Abstract Library

#4146 Anticancer activity of Cabozantinib and Temozolomide in cell lines derived from lung carcinoid and pancreatic neuroendocrine tumors

Introduction: Limited therapeutic options are available for patients with advanced neuroendocrine neoplasms (NENs). Cabozantinib (CBZ), a tyrosine kinase inhibitor including c-MET pathway, and Temozolomide (TMZ), an alkylating agent enhancing the anti-angiogenic effect of CBZ, are emerging as promising treatments in NENs.

Conference:

Presenting Author:

Authors: Tornesello M, Starita N, Clemente O, Cerasuolo A, Bracigliano A,

Keywords: cabozantinib, temozolomide, neuroendocrine tumor, cell lines, in vitro study,

#3483 A phase II single arm interventional trial evaluating the activity and safety of combination between CABOzantinib and TEMozolomide (TMZ) in lung and GEP-NENs progressive after SSAs, everolimus, sunitinib or PRRT-CABOTEM

Introduction: Cabozantinib (Cbz), a tyrosine kinase inhibitor, and Temozolomide (TMZ), an alkylating agent, show relevant clinical implications in neuroendocrine neoplasms (NENS). In glioma patients, the combination of Cbz and TMZ was well tolerated even with the addition of radiotherapy. It is possible to hypothesize a synergistic combination of Cbz and TMZ. Cbz, through the inhibition of the c-MET pathway, could enhance the sensitivity of NENs to TMZ. In addition, the intermittent metronomic schedule of TMZ has a proven anti-angiogenic activity that could be additive and/or enhance the anti-angiogenic effect of Cbz.

Conference:

Presenting Author:

Authors: Clemente O, Starita N, Cives M, Bracigliano A, Badalamenti G,

Keywords: neuroendocrine, Cabozantinb, Temozolomide, treatment, clinical trial, NEN,